Neutralizing Anti-Influenza Virus Monoclonal Antibodies: Therapeutics and Tools for Discovery

REFERENCES

• Megan L., Shaw P. P. Orthomyxoviridae: The Viruses and Their Replication. Lippincott Williams and Wilkins, Philadelphia 2007
   Google Scholar
• Reid A. H., Taubenberger J. K. The origin of the 1918 pandemic influenza virus: A continuing enigma. J Gen Virol 2003; 84: 2285–2292
   PubMed Web of Science ®Google Scholar
• Ahmed R., Oldstone M. B., Palese P. Protective immunity and susceptibility to infectious diseases: Lessons from the 1918 influenza pandemic. Nat Immunol 2003; 8: 1188–1193
   Google Scholar
• Casadevall A., Scharff M. D. Return to the past: The case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21: 150–161
   PubMed Web of Science ®Google Scholar
• Good R. A., Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer 1991; 68: 1415–1421
   PubMed Web of Science ®Google Scholar
• Luke T. C., Kilbane E. M., Jackson J. L., Hoffman S. L. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?. Ann Intern Med 2006; 145: 599–609
   PubMed Web of Science ®Google Scholar
• Wang J. P., Kurt-Jones E. A., Finberg R. W. Innate immunity to respiratory viruses. Cell Microbiol 2007; 9: 1641–1646
   PubMed Web of Science ®Google Scholar
• Fernandez-Sesma A., Moran T. M. Role of the influenza virus nonstructural 1 protein in evasion of immunity. Future Virol 2007; 2: 389–399
   Google Scholar
• Thomas P. G., Keating R., Hulse-Post D. J., Doherty P. C. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12: 48–54
   PubMed Web of Science ®Google Scholar
• Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 2001; 260: 171–190
   PubMed Web of Science ®Google Scholar
• Gerhard W., Mozdzanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 1997; 159: 95–103
   PubMed Web of Science ®Google Scholar
• Tarlinton D. M. Evolution in miniature: Selection, survival, and distribution of antigen reactive cells in the germinal centre. Immunol Cell Biol 2008; 86: 133–138
   PubMed Web of Science ®Google Scholar
• Reading S. A., Dimmock N. J. Neutralization of animal virus infectivity by antibody. Arch Virol 2007; 152: 1047–1059
   PubMed Web of Science ®Google Scholar
• Knossow M., Gaudier M., Douglas A., et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 2002; 302: 294–298
   PubMed Web of Science ®Google Scholar
• Mozdzanowska K., Maiese K., Furchner M., Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999; 254: 138–146
   PubMed Web of Science ®Google Scholar
• Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995; 69: 2075–2081
   Google Scholar
• Putz M. M., Alberini I., Midgley C. M., Manini I., Montomoli E., Smith G. L. Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol 2005; 86: 2955–2960
   Google Scholar
• Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171: 4969–4973
   PubMed Web of Science ®Google Scholar
• Yu X. Neutralizing antibodies derived from the B cells of 1918 pandemic survivors. Nature 2008; 455: 532–536
   PubMed Web of Science ®Google Scholar
• Manz R. A., Hauser A. E., Hiepe F., Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005; 23: 367–386
   PubMed Web of Science ®Google Scholar
• Manz R. A., Thiel A., Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997; 388: 133–134
   PubMed Web of Science ®Google Scholar
• Slifka M. K., Antia R., Whitmire J. K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8: 363–372
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A., Bernasconi N., Traggiai E., Ruprecht C. R., Corti D., Sallusto F. Understanding and making use of human memory B cells. Immunol Rev 2006; 211: 303–309
   PubMed Web of Science ®Google Scholar
• Manz R. A., Radbruch A. Plasma cells for a lifetime?. Eur J Immunol 2002; 32: 923–927
   Google Scholar
• Brieva J. A., Roldan E., De la Sen M. L., Rodriguez C. Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood, and bone marrow exhibit different phenotype and functional level of maturation. Immunology 1991; 72: 580–583
   PubMed Web of Science ®Google Scholar
• Tokoyoda K., Egawa T., Sugiyama T., Choi B. I., Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004; 20: 707–718
   PubMed Web of Science ®Google Scholar
• Gerhard W. The analysis of the monoclonal immune response to influenza virus. II. The antigenicity of the viral hemagglutinin. J Exp Med 1976; 144: 985–995
   Google Scholar
• Shaw M. L., Palese P. Lippincott Williams & Wilkins. 2007
   Google Scholar
• World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1). 2008, Reported to WHO, Geneva
   Google Scholar
• Caton A. J., Brownlee G. G., Yewdell J. W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31: 417–427
   PubMed Web of Science ®Google Scholar
• Raymond F. L., Caton A. J., Cox N. J., Kendal A. P., Brownlee G. G. Antigenicity and evolution amongst recent influenza viruses of H1N1 subtype. Nucl Acids Res 1983; 11: 7191–7203
   Google Scholar
• Both G. W., Sleigh M. J., Cox N. J., Kendal A. P. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: Multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 1983; 48: 52–60
   PubMed Web of Science ®Google Scholar
• Wiley D. C., Wilson I. A., Skehel J. J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289: 373–378
   PubMed Web of Science ®Google Scholar
• Fuller H., Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev 2006, CD004883
   Google Scholar
• Hemming V. G. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol 2001; 8: 859–863
   PubMedGoogle Scholar
• Marasco W. A., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25: 1421–1434
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A., Corti D., Sallusto F. Human monoclonal antibodies by immortalization of memory B cells. Curr Opin Biotechnol 2007; 18: 523–528
   PubMedGoogle Scholar
• Kashyap A. K., Steel J., Oner A. F., et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 2008; 105: 5986–5991
   PubMed Web of Science ®Google Scholar
• Basler C. F., Aguilar P. V. Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res 2008; 79: 166–178
   PubMed Web of Science ®Google Scholar
• World Health Organization. Towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses. Geneva 2007
   Google Scholar
• Wu W. L., Chen Y., Wang P., et al. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol 2008; 82: 1798–1807
   PubMed Web of Science ®Google Scholar
• Throsby M., Geuijen C., Goudsmit J., et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 2006; 80: 6982–6992
   PubMed Web of Science ®Google Scholar
• ter Meulen J., Bakker A. B., van den Brink E. N., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004; 363: 2139–2141
   PubMed Web of Science ®Google Scholar
• ter Meulen J., van den Brink E. N., Poon L. L., et al. Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med 2006; 3: e237
   PubMed Web of Science ®Google Scholar
• Meijer P.-J., Andersen P. S., Haahr Hansen M., et al. Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol Biol 2006; 358: 764–772
   PubMed Web of Science ®Google Scholar
• Almagro J. C., Fransson J. Humanization of antibodies. Front Biosci 2008; 13: 1619–1633
   PubMed Web of Science ®Google Scholar
• Kabat E. A., Wu T. T., Reid-Miller M., Perry H. M., Gottesman K. S. Sequences of Proteins of Immunological Interest. National Institutes of Health, Bethesda 1987
   Google Scholar
• Lefranc M. P. The Immunoglobulin Facts Book. Academic Press, London 2001
   Google Scholar
• Hanson B. J., Boon A. C., Lim A. P., Webb A., Ooi E. E., Webby R. J. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7: 126
   PubMed Web of Science ®Google Scholar
• Kaverin N. V., Rudneva I. A., Govorkova E. A., et al. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 2007; 81: 12911–12917
   PubMed Web of Science ®Google Scholar
• Gerhard W., Yewdell J., Frankel M. E., Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 1981; 290: 713–717
   PubMed Web of Science ®Google Scholar
• Wiley D. C., Skehel J. J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56: 365–394
   PubMed Web of Science ®Google Scholar
• Kaverin N. V., Rudneva I. A., Ilyushina N. A., Lipatov A. S., Krauss S., Webster R. G. Structural differences among hemagglutinins of influenza A virus subtypes are reflected in their antigenic architecture: Analysis of H9 escape mutants. J Virol 2004; 78: 240–249
   Web of Science ®Google Scholar
• Kaverin N. V., Rudneva I. A., Ilyushina N. A., et al. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 2002; 83: 2497–2505
   PubMed Web of Science ®Google Scholar
• Coughlin M., Lou G., Martinez O., et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 2007; 361: 93–102
   PubMed Web of Science ®Google Scholar
• Sloan S. E., Hanlon C., Weldon W., et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 2007; 25: 2800–2810
   PubMed Web of Science ®Google Scholar
• Greenough T. C., Babcock G. J., Roberts A., et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 2005; 191: 507–514
   PubMed Web of Science ®Google Scholar
• He Y., Honnen W. J., Krachmarov C. P., et al. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J Immunol 2002; 169: 595–605
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cumulative Number of Reported Cases (SARS)
   Google Scholar
• World Health Organization. Geneva 2006, Rabies Fact Sheet No. 99
   Google Scholar
• DeVincenzo J. P., Hall C. B., Kimberlin D. W., et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) resistant mutants. J Infect Dis 2004; 190: 975–978
   PubMed Web of Science ®Google Scholar
• Jakobovits A., Amado R. G., Yang X., Roskos L., Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25: 1134–1143
   PubMed Web of Science ®Google Scholar
• Nagata N., Iwata N., Hasegawa H., et al. Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice. Am J Pathol 2008; 172: 1625–1637
   PubMed Web of Science ®Google Scholar
• Wrammert J., Smith K., Miller J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453: 667–671
   PubMed Web of Science ®Google Scholar
• Simmons C. P., Bernasconi N. L., Suguitan A. L., et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4: e178
   PubMedGoogle Scholar
• Tian C., Luskin G. K., Dischert K. M., Higginbotham J. N., Shepherd B. E., Crowe J. E., Jr. Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naive and memory B cells. Mol Immunol 2007; 44: 2173–2183
   Google Scholar
• Tumpey T. M., Basler C. F., Aguilar P. V., et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005; 310: 77–80
   PubMed Web of Science ®Google Scholar
• Stevens J., Corper A. L., Basler C. F., Taubenberger J. K., Palese P., Wilson I. A. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004; 303: 1866–1870
   PubMed Web of Science ®Google Scholar
• Gamblin S. J., Haire L. F., Russell R. J., et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004; 303: 1838–1842
   PubMed Web of Science ®Google Scholar